1 Readers
were masked to all eye examination results, previous gradings
2 Data collectors and the data manager
were masked to allocation.
3 ors, patients, site personnel, and those assessing outcomes
were masked to dose group allocation.
4 Research staff who obtained outcome measurements
were masked to group allocation and clinical staff who delive
5 , PTC Therapeutics employees, and all other study personnel
were masked to group allocation until after database lock.
6 research assistant, but the remainder of the research team
were masked to group allocation.
7 Investigators who did the analyses
were masked to group allocation.
8 y participants, investigators, study staff, and the sponsor
were masked to group assignment until all participants had co
9 patients, investigators, their site personnel, and sponsor
were masked to group assignment.
10 Only statisticians
were masked to group.
11 ence of delirium was assessed daily by 2 trained nurses who
were masked to intervention status by using the Confusion Ass
12 atal interstitial glucose concentrations; outcome assessors
were masked to neonatal glycemic status.
13 Clinicians
were masked to neonatal interstitial glucose concentrations;
14 9 months post baseline were done by follow-up assessors who
were masked to participants' group and counsellor allocation.
15 Participants, ward staff, and outcome assessors
were masked to randomisation where possible; masking was obvi
16 The analysts and investigators with access to the raw data
were masked to study group by coding the groups until after t
17 nts and all clinicians other than the DBS programming nurse
were masked to the choice of lead.
18 radiologists, study team, and anyone involved in the study
were masked to the identity of the treatment until unblinding
19 Team members
were masked to the postoperative outcomes.
20 baseline, 12 weeks, and 24 weeks, by research assessors who
were masked to therapy allocation.
21 Investigators and participants
were masked to treatment allocation, and an unmasked team of
22 y, and the patients, investigators, and central study staff
were masked to treatment allocation.
23 Participants and site staff
were masked to treatment allocation.
24 Patients, investigators, and trial personnel
were masked to treatment allocation.
25 Neither patients nor study staff
were masked to treatment allocation.
26 Patients, investigators, and those completing data analyses
were masked to treatment allocation.
27 abel, but investigators assessing primary efficacy outcomes
were masked to treatment allocation.
28 my, and the patient, investigators, and central study staff
were masked to treatment allocation.
29 Patients, treating physicians, and outcome assessors
were masked to treatment allocation.
30 Study site staff and participants
were masked to treatment assignment from enrolment through we
31 Patients and investigators (including local radiologists)
were masked to treatment assignment from randomisation until
32 Patients, investigators, staff, and outcome assessors
were masked to treatment assignment.
33 s, and study personnel, including those assessing outcomes,
were masked to treatment assignment.
34 eating physician, clinical research staff, and participants
were masked to treatment assignment.
35 clinical research organisation, investigators, and patients
were masked to treatment assignment.
36 ts of participants and clinical, data, and laboratory staff
were masked to treatment assignment.
37 Investigators, patients, and the funder
were masked to treatment assignment.
38 Participants and investigators
were masked to treatment assignment.
39 Patients and investigators
were masked to treatment assignment.
40 Patients, study investigators, and study sponsor personnel
were masked to treatment assignment.
41 All study personnel and participants
were masked to treatment assignment.
42 Patients, investigators, and clinicians
were masked to treatment assignment.
43 Patients and investigators
were masked to treatment assignments.
44 Patients, investigators, and study staff
were masked to treatment assignments.
45 All study staff and patients
were masked to treatment group allocation.
46 rs, participants, study staff, and those assessing outcomes
were masked to treatment group.
47 nt, collecting data, and assessing outcomes, and the funder
were masked to treatment group.
48 ICU clinical and research staff and patients
were masked to treatment.
49 Both patients and investigators
were masked to treatment.
50 study team, and members of the adjudication pathology panel
were masked to vaccination groups.